Track record · closed signal

Innoviva Inc (INVA) — closed signal from May 12, 2026

Partial Published before the outcome was known, scored automatically when the window closed on August 10, 2026 — -9.2% at the close.

Predicted vs. what happened

INVA price · publication thesis → realized outcomesplit-adjusted

$21.75 – $23.25Entry zone — fair-value band

$22.77Published — price the day we called it

$27.78Target — the price the thesis aimed for

$24.17Peak — highest point inside the window, not a realized return

$20.68Window close — end-of-window price, context only

What happened

Partial

Reached 28% of the predicted growth at its peak, without hitting the target.

At window close

-9.2%

realized, from the publication price to the last close inside the window

Peak gain

+6.1%

peak, from the publication price — not a realized return

S&P 500, same window

+5%

SPY over the identical days, dividend-adjusted

Window close

$20.68

last close inside the window, ended August 10, 2026

Peak price

$24.17

peak on June 24, 2026 — not a realized return

Days to target

—

The thesis — published May 12, 2026

Predicted growth

+22%

over the measurement window

Target price

$27.78

the price the thesis aimed for

Entry zone

$21.75 – $23.25

the fair-value band we waited for

Price at publication

$22.77

published May 12, 2026

Confidence

70%

how strongly the data lined up

Timeframe

Short-term (0–3 months)

Innoviva pays recurring royalties that create steady cash, sits on strong cash reserves, and the market expects little growth. Positive analyst news about those royalties gives a clear reason to watch the stock. Trading is light, short selling is notable, and technical signals show weakness, so the setup is attractive but sensitive to low liquidity.

Primary drivers

Royalty payments create predictable cash flow over time
Recent analyst focus emphasizes the steady royalty base
Healthy cash balance helps limit downside risk
Low trading volume makes price moves more volatile

How it played out

INVA: the 22% growth thesis missed

Lyra published INVA at $22.77 with expected growth of 22% and a $27.78 target. The thesis pointed to recurring royalty cash flow, healthy cash reserves, recent analyst attention on the royalty base, and low trading volume. It also noted short selling, technical weakness, and sensitivity to low liquidity.

The shares peaked at $24.17 on June 24, a gain of 6.1%. They stayed below the target throughout the window and ended at $20.68 on August 10. The thesis did not play out.

What happened during the window

On June 16, 2026, Innoviva announced an exclusive distribution and licensing agreement with Dr. Reddy's for XACDURO in selected international markets. On August 5, 2026, the company reported second-quarter royalty revenue of $59.8 million.

Prices are shown split- and dividend-adjusted, matching what public charts show today.

Lyra

Read the next call before it closes.

This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.

See today’s picks All INVA signals